Drug Approval | June 27, 2023
USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
The partnership will capitalize on the combined capabilities of the two organizations
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Digitization has unleashed a flood of data that presents a huge opportunity but is also overwhelming clinicians, nurses, and administrators
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
Subscribe To Our Newsletter & Stay Updated
